EPCORE NHL-6: SC epcoritamab (CD3×CD20) enables outpatient R/R DLBCL dosing with 64% ORR and 27.2-mo mOS

Epcoritamab is a subcutaneous CD3×CD20 bispecific T-cell engager (already approved in the US for R/R DLBCL) evaluated in the Phase 2 EPCORE NHL-6 outpatient-feasibility study in 2L+ R/R DLBCL across US/Puerto Rico sites (n=92; NCT05451810) using step-up dosing then 48 mg weekly→Q2W→Q4W. At 17.3 months median follow-up (data cutoff November 11, 2025), efficacy was ORR 64.1% and CRR 48.9% overall, with mDOR 25.8 months, mPFS 7.9 months, and mOS 27.2 months; outcomes were numerically better in 2L patients (n=42) with ORR 66.7%, CRR 57.1%, and mPFS 11.4 months (mOS NR). Safety remained consistent with prior epcoritamab reports, but still heavy: Grade 3–4 TEAEs 81.5%, Grade 5 TEAEs 17.4% (including 5.4% infection-related deaths; 3.3% COVID-19), serious AEs 65.2%, infections 68.5% (26.1% serious), and 22.8% discontinued due to TEAEs—benchmarking against pola-BR in transplant-ineligible R/R DLBCL (ORR ~41.5%, CR ~38.7%, mPFS ~6.6 mo, mOS ~12.5 mo), the survival/durability here look meaningfully longer, albeit with cross-trial and population caveats.